全球血小板聚集設備市場規模、份額和趨勢分析報告—產業概況和2032年預測

血小板聚集設備市場規模

• 2024 年全球血小板聚集設備市場規模為9.2745 億美元，預計到 2032 年將達到 14.4 億美元，預測期內 複合年增長率為 5.67%。
• 這一增長是由心血管和循環系統疾病患病率上升、技術進步和老年人口增加等因素推動的

血小板聚集設備市場分析

• 血小板聚集裝置是評估血小板功能、檢測凝血障礙和監測抗血小板療法有效性的重要工具。這些設備在心血管疾病、出血性疾病和血栓性疾病的診斷和管理中發揮著至關重要的作用
• 這些設備的需求很大程度上受到心血管疾病盛行率上升、老年人口增加以及診斷技術的進步的推動。此外，人們對血小板相關疾病的認識不斷提高以及早期診斷的重要性進一步推動了市場的成長
• 北美預計將以 39.98% 的份額佔據全球血小板聚集設備市場主導地位，因為其擁有先進的醫療基礎設施、心血管和血液疾病的高發病率以及領先的醫療器械製造商的強大影響力
• 亞太地區預計將成為全球血小板聚集設備市場成長最快的地區，佔總市場份額的 25.6%，這得益於醫療基礎設施的快速擴張、人們對心血管健康的認識不斷提高以及對先進診斷工具的需求不斷增長
• 由於臨床和研究環境中對血小板功能檢測所必需的試劑、檢測試劑盒和一次性組件的需求持續增長，預計耗材和配件部分將佔據市場主導地位，市場份額為 76.2%

報告範圍和血小板聚集設備市場細分        

血小板聚集設備市場趨勢

“血小板聚集裝置的技術進步”

• 血小板聚集設備市場的一個突出趨勢是開發先進的自動化系統，以提供更準確、快速且可靠的血小板功能測試
• 這些創新透過結合即時數據分析、高通量處理和數位連接來提高診斷準確性，從而提高臨床和研究環境的效率 
  • 例如，下一代血小板聚集儀利用光學和基於阻抗的技術來精確測量血小板功能，從而可以更好地檢測凝血障礙和評估抗血小板療法。這些系統還與醫院資訊系統集成，簡化數據管理並改善臨床決策 
• 這些進步正在改變血小板檢測，改善患者的治療效果，並推動對具有更高準確性和易用性的創新血小板聚集設備的需求

血小板聚集設備市場動態

司機

“心血管疾病發生率上升”

• 心臟病、中風和周邊動脈疾病等心血管疾病（CVD）的盛行率不斷上升，是血小板聚集設備市場的主要驅動力
• 隨著全球人口老化和生活方式變得更加久坐，心血管疾病的發生率持續上升，對評估血小板功能和監測抗血小板治療的診斷工具的需求也隨之增加
• 血小板聚集測試在管理這些疾病方面起著至關重要的作用，可以幫助醫療保健專業人員評估血栓形成的風險並制定個人化的治療方案

例如，

• 根據世界衛生組織 (WHO) 的預測，到 2025 年，心血管疾病預計仍將是全球最大的死亡原因，每年導致近 1800 萬人死亡。心臟病負擔日益加重，凸顯了對血小板聚集裝置等有效診斷工具的迫切需求 
• 因此，由於對心血管疾病早期診斷和有效管理的需求，預計血小板聚集裝置的需求將大幅增加

機會

“血小板功能檢測的技術進步”

• 血小板聚集設備的不斷創新促進了更準確、自動化和用戶友好的系統的開發，從而改變了評估血小板功能的方式
• 光學和基於阻抗的聚集度測量等先進技術可提供即時、高精度的結果，從而實現更好的臨床決策和個人化的患者護理
• 此外，即時診斷（POC）血小板聚集設備越來越受歡迎，可以在緊急情況和重症監護環境中進行快速的現場檢測

例如，

• 2024 年，多家公司推出了新一代血小板聚集儀，該設備具有增強的數據分析能力、數位連接以及與電子健康記錄 (EHR) 的集成，從而提高了工作流程效率和患者治療效果 
• 這些技術進步為血小板聚集設備市場創造了巨大的成長機會，這得益於精準診斷和個人化醫療需求的不斷增長

克制/挑戰

“先進測試系統成本高昂”

• 儘管先進的血小板聚集設備有許多好處，但其高昂的成本可能會成為其廣泛採用的重大障礙，尤其是在發展中地區
• 這些系統通常需要專門的設備、定期維護和訓練有素的人員，這增加了測試的整體成本
• 預算有限的小型醫療機構可能難以投資這些技術，從而導致依賴較老、較不準確的檢測方法

例如，

• 2024 年，美國國家生物技術資訊中心的一份報告強調了先進血小板檢測系統帶來的經濟負擔，這可能會限制其在資源受限環境中的普及 
• 因此，這些設備的高成本可能會限制市場成長，造成病患照護品質和獲得先進診斷工具的差異

血小板聚集設備市場範圍

市場根據產品類型、應用和最終用戶進行細分。

In 2025, the consumables and accessories is projected to dominate the market with a largest share in product type segment

The consumables and accessories segment is expected to dominate the platelet aggregation devices market with the largest share of 76.2% in 2025, due to the continuous demand for reagents, test kits, and disposable components essential for platelet function testing in both clinical and research settings. As critical components in platelet aggregation testing, these consumables ensure a steady revenue stream for manufacturers. Advancements in testing methodologies and the expansion of platelet aggregation testing applications further contribute to the market dominance of this segment.

The clinical applications is expected to account for the largest share during the forecast period in technology market

In 2025, the clinical applications segment is expected to dominate the market with the largest market share of 62.5%, primarily due to the increasing use of platelet aggregation testing in clinical diagnostics for monitoring patients with thrombotic disorders, cardiovascular diseases, and other conditions involving platelet dysfunction. The growing emphasis on personalized healthcare and patient-specific treatment plans has intensified the demand for precise platelet function assessments, further driving the growth of this segment.

Platelet Aggregation Devices Market Regional Analysis

“North America Holds the Largest Share in the Platelet Aggregation Devices Market”

• North America accounted for the largest share of 39.98% in the global platelet aggregation devices market because of its advanced healthcare infrastructure, high prevalence of cardiovascular and hematological disorders, and strong presence of leading medical device manufacturers.
• U.S., accounts for 40.1% share within North America, held a substantial portion of this market share, driven by advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and a strong presence of key market players
• The region's dominance is further supported by well-established reimbursement policies and growing investments in research & development by leading medical device companies
• In addition, the increasing number of diagnostic procedures, along with a high rate of adoption of minimally invasive techniques, is fueling market expansion across the region

“Asia-Pacific is Projected to Register the Highest CAGR in the Platelet Aggregation Devices Market”

• Asia-Pacific is anticipated to grow at the fastest rate during the forecast period, with market share of 25.6%, driven by rapid expansion in healthcare infrastructure, increasing awareness about cardiovascular health, and rising demand for advanced diagnostic tools
• Countries such as China, India, and Japan are emerging as key markets due to the growing prevalence of cardiovascular diseases, aging populations, and rising healthcare expenditures
• Japan, with its advanced medical technology and increasing number of specialized diagnostic centers, remains a crucial market for platelet aggregation devices. The country continues to lead in the adoption of premium diagnostic equipment to enhance patient outcomes and efficiency in clinical settings
• India is projected to register the highest CAGR in the platelet aggregation devices market, driven by expanding healthcare infrastructure, increasing awareness about cardiovascular health, and rising diagnostic testing volumes

Platelet Aggregation Devices Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• AggreDYNE, Inc. (U.S.)
• BIO/DATA CORPORATION (U.S.)
• Chrono-Log Corporation (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Haemonetics Corporation (U.S.)
• Siemens Healthineers AG (Germany)
• Werfen (Spain)
• Sysmex Corporation (Japan)
• Sienco, Inc. (U.S.)
• Drucker Diagnostics (U.S.)
• Helena Laboratories Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Grifols, S.A. (Spain)
• SENTINEL CH. SpA (Italy)
• Stago (France)
• Hart Biologicals (U.K.)
• LABiTec (Germany)

Latest Developments in Global platelet aggregation devices market

• In January 2025, Haemonetics Corporation, a global leader in blood and platelet management, announced the launch of its new Platelet Function Analyzer 5000. The device provides enhanced accuracy and efficiency for platelet aggregation testing, enabling better monitoring of platelet function during therapeutic interventions. This innovation will be crucial in optimizing treatment regimens for patients with thrombotic disorders and improving clinical outcomes
• 2024年10月，Bio/Data公司在美國血液學會會議上展示了其最新的PFA-100血小板功能 分析儀。該設備旨在提供即時、高通量的血小板功能分析，增強醫療保健提供者管理出血性疾病和心血管疾病的診斷能力。該系統整合了先進的技術，可提供更可靠的檢測結果，從而實現更好的針對患者的治療策略
• 2024 年 9 月，Chrono-Log 公司推出了升級版 700 型血小板 聚集系統。新系統提高了血小板聚集檢測的精確度，並加快了數據處理速度，使醫療保健提供者能夠在治療血小板功能障礙患者時做出更快、更明智的決策。升級還包括用於更全面的數據分析和更好的臨床決策的新軟體
• 2024 年 9 月，維爾芬推出了多板分析儀，一種用於測量血小板功能的尖端設備。該設備以其用戶友好的介面和檢測血小板功能障礙的高靈敏度而聞名，這對於血栓性疾病的診斷和管理至關重要。該公司將進一步擴展該設備的功能，並增加軟體增強功能，以輔助個人化患者護理

SKU-14215